KCM
Kynam Capital Management Portfolio holdings
AUM
$929M
This Quarter Return
+31.72%
1 Year Return
-7.66%
3 Year Return
+163.82%
5 Year Return
–
10 Year Return
–
AUM
$884M
AUM Growth
+$884M
(+47%)
Cap. Flow
+$129M
Cap. Flow
% of AUM
14.56%
Top 10 Holdings %
Top 10 Hldgs %
80.12%
Holding
32
New
3
Increased
10
Reduced
5
Closed
7
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$44.5M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$42.2M |
| 3 |
MOR
MorphoSys AG American Depositary Shares
MOR
|
$41.9M |
| 4 |
Cogent Biosciences
COGT
|
$21.4M |
| 5 |
Dynavax Technologies
DVAX
|
$14.2M |
Top Sells
| 1 |
Natera
NTRA
|
$37.8M |
| 2 |
Vaxcyte
PCVX
|
$18.8M |
| 3 |
Taysha Gene Therapies
TSHA
|
$10.4M |
| 4 |
Celldex Therapeutics
CLDX
|
$7.7M |
| 5 |
Olema Pharmaceuticals
OLMA
|
$2.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Gossamer Bio
GOSS
$587M
| – | – |
-250,000
| Closed | -$208K |
|
27
Gyre Therapeutics
GYRE
$734M
| – | – |
-90,058
| Closed | -$43.4K |
|
28
Immunovant
IMVT
$2.91B
| – | – |
0
| – | – |
|
29
Neurogene
NGNE
$284M
| – | – |
-24,037
| Closed | -$94.9K |
|
|
30
Olema Pharmaceuticals
OLMA
$432M
| – | – |
-235,176
| Closed | -$2.9M |
|
31
Puma Biotechnology
PBYI
$258M
| – | – |
-473,975
| Closed | -$1.25M |
|
|
32
Taysha Gene Therapies
TSHA
$791M
| – | – |
-3,281,313
| Closed | -$10.4M |
|